Abstract
Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is a synthetic drug from the family of nonsteroidal anti-inflammatory drugs (NSAIDs) used for inflammatory diseases of the gastrointestinal tract. However, 5-ASA has also been used for various other diseases due to its pharmacological effects, but they are usually scattered across various publications, which may limit further research and clinical use of this drug. This review is a summary of published information on the biological and pharmacological effects of 5-ASA with the aim of identifying its anti-oxidant role and medicinal use. 5-ASA data have been collected from 1987 to February 2021 using major databases such as Web of Science, PubMed, Elsevier, Wiley Online Library, Springer, Google Scholar, etc. According to research, the pharmacological and biological effects of 5-ASA include treatment of inflammatory bowel disease, and anti-oxidant, anti-inflammatory, antibacterial, antifungal, anticancer, anti-amyloid, gastric protection (gastroprotective), and antidiverticulosis properties. Numerous pharmacological studies have shown that 5-ASA is an anti-oxidant and anti-ulcer compound with high therapeutic potential that, if the appropriate dose is discovered, its chemical structure changes and its effectiveness is optimized, 5-ASA has been used experimentally for other diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdu-Allah HH, El-Shorbagi A, Abdel-Moty SG, El-Awady R, Abdel-Alim A (2016) 5-Aminosalyclic acid (5-ASA): a unique anti-inflammatory salicylate. Med Chem (Los Angeles) 6:306–315. https://doi.org/10.4172/2161-0444.1000361
Ahnfelt-Rønne I, Nielsen OH (1987) The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions 21(1):191–194. https://doi.org/10.1007/BF01974941
Ahnfelt-Rønne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P (1990) Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98(5):1162–1169. https://doi.org/10.1016/0016-5085(90)90329-Y
Allgayer H (2003) Mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 18:10–14. https://doi.org/10.1046/j.1365-2036.18.s2.1.x
Allgayer H, Höfer P, Schmidt M, Böhne P, Kruis W, Gugler R (1992) Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates: direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol 43(2):259–262. https://doi.org/10.1016/0006-2952(92)90286-R
Andrews C, Griffiths T, Kaufman J, Vergnolle N, Surette M, Rioux K (2011) Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 34(3):374–383. https://doi.org/10.1111/j.1365-2036.2011.04732.x
Aslan A, Temiz M, Atik E, Polat G, Sahinler N, Besirov E, Aban N, Parsak CK (2007) Effectiveness of mesalamine and propolis in experimental colitis. Adv Ther 24(5):1085–1097. https://doi.org/10.1007/BF02877715
Banaei S (2016) The effect of 5-aminosalicylic acid on renal ischemia-reperfusion injury in rats. Indian J Pharmacol 48(2):196. https://doi.org/10.4103/0253-7613.178840
Bardineshin F (2021) Evaluation of inhibitory and unstable effects of mesalazine on insulin protein fibrillation: a strategy to reduce the effects of subcutaneous insulin accumulation due to repeated injections in diabetic patients. MSc Thesis, Lorestan University, Lorestan, Iran, (In Persian). https://ganj.irandoc.ac.ir/#/articles/343f4e98eeb0b9288a7b65571309c2fe
Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU (2005) Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol 40(8):958–964. https://doi.org/10.1080/00365520510015854
Beiranvand M (2020) The protective and antioxidant effects of Eremurus persicus (Jaub & Spach) Boiss extract and mesalazine on ethanol-induced gastric Damages in Rats. MSc Thesis, Lorestan University, Lorestan, Iran, (In Persian). https://ganj.irandoc.ac.ir/#/articles/f8c4a293f8a35968e928418e961cf6c9
Beiranvand M, Bahramikia S (2020) Ameliorating and protective effects mesalazine on ethanol-induced gastric ulcers in experimental rats. Eur J Pharmacol 888:173573. https://doi.org/10.1016/j.ejphar.2020.173573
Beiranvand M, Beiranvand F (2021) Iranian plant Eremurus persicus: an overview of botany, traditional uses, phytochemistry and pharmacology. Nat Prod Res 35:1-15. https://doi.org/10.1080/14786419.2021.1916744
Bharti R (1996) Mesalazine in treatment of psoriasis. Indian J Dermatol Venereol Leprol 62(4):231–232
Buchner AM, Lichtenstein GR (2019) Mesalazine and mucosal microbiome in quiescent ulcerative colitis—what can we learn? Aliment Pharmacol Ther 49(12):1531–1531. https://doi.org/10.1111/apt.15281
Canevari M, Castagliuolo I, Brun P, Cardin M, Schiavon M, Pasut G, Veronese F (2009) Poly (ethylene glycol)-mesalazine conjugate for colon specific delivery. Int J Pharm 368(1–2):171–177. https://doi.org/10.1016/j.ijpharm.2008.09.058
Caprilli R, Andreoli A, Capurso L, Corrao G, AlbasioGioieniAssueroLanfranchiPaladiniPallonePonti GAGIFV (1994) Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn’s disease. Aliment Pharmacol Ther 8(1):35–43. https://doi.org/10.1111/j.1365-2036.1994.tb00158.x
Cheng W, Li J, Liu X (2020) 5-Aminosalicylic acid for treatment of irritable bowel syndrome: a protocol for a systematic review and meta-analysis. Medicine 99(9):e19351. https://doi.org/10.1097/MD.0000000000019351
Cho C, Ogle C, Sevilla E (1987) The protective effects of sulphasalazine against ethanol-induced gastric damage in rats. Br J Pharmacol 92(1):31. https://doi.org/10.1111/j.1476-5381.1987.tb11292.x
Chu E, Chai J, Ahluwalia A, Tarnawski A (2007) Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Ther 25(12):1443–1449. https://doi.org/10.1111/j.1365-2036.2007.03336.x
Ci L (2014) Mesalamine Handbook of metabolic pathways of xenobiotics. New York: Wiley, pp 1–3. https://doi.org/10.1002/9781118541203.xen314
Comparato G, Fanigliulo L, Cavallaro LG, Aragona G, Cavestro GM, Iori V, Maino M, Mazzocchi G, Muzzetto P, Colla G (2007) Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 52(11):2934–2941. https://doi.org/10.1007/s10620-007-9766-8
Conner EM, Grisham MB (1996) Inflammation, free radicals, and antioxidants. Nutrition 12(4):274–277. https://doi.org/10.1016/S0899-9007(96)00000-8
Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro R, De Giorgio R, Bartesaghi G, Canovi B, Barbara G (2009) Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 30(3):245–252. https://doi.org/10.1111/j.1365-2036.2009.04041.x
Couto D, Ribeiro D, Freitas M, Gomes A, Lima JL, Fernandes E (2010) Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine. Redox Rep 15(6):259–267. https://doi.org/10.1179/135100010X12826446921707
Day BJ, Huang J, Barkes BQ, Gillespie M, Li L, Maier LA (2018) 5-Aminosalicylic acid modulates the immune response in chronic beryllium disease subjects. Lung 196(1):103–114. https://doi.org/10.1007/s00408-017-0062-x
Di Mario F, Aragona G, Leandro G, Comparato G, Fanigliulo L, Cavallaro LG, Cavestro GM, Iori V, Maino M, Moussa AM (2005) Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 50(3):581–586. https://doi.org/10.1007/s10620-005-2478-z
Dixon SW, Collard TJ, Mortensson EMH, Legge DN, Chambers AC, Greenhough A, Creed TJ, Williams AC (2021) 5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. Br J Cancer 124(12):1959–1969. https://doi.org/10.1038/s41416-021-01354-5
Faramarzian M, Bahramikia S, Shasaltaneh MD (2020) In vitro investigation of the effect of mesalazine on amyloid fibril formation of hen egg-white lysozyme and defibrillation lysozyme fibrils. Eur J Pharmacol 874:173011. https://doi.org/10.1016/j.ejphar.2020.173011
Faramarzpour A, Tehrani AA, Tamaddonfard E, Imani M (2019) The effects of crocin, mesalazine and their combination in the acetic acid-induced colitis in rats. Vet Res Forum 10(3):227–234. https://doi.org/10.30466/vrf.2019.35900
Garg G, Cho C, Ogle C (1990) Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats. Pharmacology 40(6):318–324. https://doi.org/10.1159/000138680
Garjani A, Davaran S, Rashidi M, Malek N (2004) Protective effects of some azo derivatives of 5-aminosalicylic acid and their pegylated prodrugs on acetic acid-induced rat colitis. Daru 12(1):24–30
Greinwald R (2000) Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 14:1191–1198
Hatamvand V, Bardineshin F, Shohani P (2020) Anti-amyloidogenic and disaggregating effects of Salvia officinalis in vitro: a strategy to reduce the insulin amyloid fibrils due to repeated subcutaneous injections in diabetic patients. Yafteh 22(3):68–83
Hayashi Y, Aoyagi K, Morita I, Yamamoto C, Sakisaka S (2009) Oral administration of mesalazine protects against mucosal injury and permeation in dextran sulfate sodium-induced colitis in rats. Scand J Gastroenterol 44(11):1323–1331. https://doi.org/10.3109/00365520903262414
Hoffmann M, Kant TA, Emig R, Rausch JS, Newe M, Schubert M, Künzel K, Winter L, Klapproth E, Peyronnet R (2020) Repurposing mesalazine against cardiac fibrosis in vitro. Naunyn Schmiedebergs Arch Pharmacol 394:533–543. https://doi.org/10.1007/s00210-020-01998-9
Jhundoo HD, Siefen T, Liang A, Schmidt C, Lokhnauth J, Béduneau A, Pellequer Y, Larsen CC, Lamprecht A (2020) Anti-inflammatory activity of chitosan and 5-amino salicylic acid combinations in experimental colitis. Pharmaceutics 12(11):1038. https://doi.org/10.3390/pharmaceutics12111038
Joshi R, Kumar S, Unnikrishnan M, Mukherjee T (2005) Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free Radic Res 39(11):1163–1172. https://doi.org/10.1080/10715760500177880
Jung ES, Jang HJ, Hong EM, Lim HL, Lee SP, Kae SH, Lee J (2020) The protective effect of 5-aminosalicylic acid against non-steroidal anti-inflammatory drug-induced injury through free radical scavenging in small intestinal epithelial cells. Medicina 56(10):515. https://doi.org/10.3390/medicina56100515
Kang S, Kim W, Jeong S, Lee Y, Nam J, Lee S, Jung Y (2017) Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: implication in anti-inflammatory actions of 5-aminosalicylic acid. Free Radic Biol Med 108:715–724. https://doi.org/10.1016/j.freeradbiomed.2017.04.366
Kaufman J, Griffiths TA, Surette MG, Ness S, Rioux KP (2009) Effects of mesalamine (5-5-aminosalicylic acid) on bacterial gene expression. Inflamm Bowel Dis 15(7):985–996. https://doi.org/10.1002/ibd.20876
Kaur A, Goggolidou P (2020) Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. J Inflamm 17(1):1–8. https://doi.org/10.1186/s12950-020-00246-4
Khare V, Krnjic A, Frick A, Gmainer C, Asboth M, Jimenez K, Lang M, Baumgartner M, Evstatiev R, Gasche C (2019) Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation. Sci Rep 9(1):1–11. https://doi.org/10.1038/s41598-019-39401-0
Kim Y-H, Kim M, Kim B, Kim J, Chang D, Son H, Rhee P-L, Rhee J (2009) Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid. Dig Liver Dis 41(5):328–337. https://doi.org/10.1016/j.dld.2008.09.003
Kim W, Kim D, Jeong S, Ju S, Lee H, Kim S, Yoo J-W, Yoon I-S, Jung Y (2019) Conjugation of amisulpride, an anti-psychotic agent, with 5-aminosalicylic acid via an Azo bond yields an orally active mutual prodrug against rat colitis. Pharmaceutics 11(11):585. https://doi.org/10.3390/pharmaceutics11110585
Koelink PJ, Robanus-Maandag EC, Hommes D, Verspaget HW (2009) 50 5-aminosalicylic acid suppresses colitis-associated but not sporadic colorectal cancer. Gastroenterology 5(136):A-8. https://doi.org/10.1016/S0016-5085(09)60040-8
Krieken V (1999) Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 13(11):1397–1402. https://doi.org/10.1046/j.1365-2036.1999.00652.x
Kruis W, Meier E, Schumacher M, Mickisch O, Greinwald R, Mueller R, Group GSS (2013) Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon–a placebo-controlled study. Aliment Pharmacol Ther 37(7):680–690. https://doi.org/10.1111/apt.12248
Kvietys PR, Smith SM, Grisham MB, Manci EA (1988) 5-Aminosalicylic acid protects against ischemia/reperfusion-induced gastric bleeding in the rat. Gastroenterology 94(3):733–738. https://doi.org/10.1016/0016-5085(88)90247-8
Lazić V, Smičiklas I, Marković J, Lončarević D, Dostanić J, Ahrenkiel SP, Nedeljković JM (2018) Antibacterial ability of supported silver nanoparticles by functionalized hydroxyapatite with 5-aminosalicylic acid. Vacuum 148:62–68. https://doi.org/10.1016/j.vacuum.2017.10.039
Lin HC, Pimentel M (2001) Use of 5-aminosalicylates as antimicrobial agents. Google Patents https://patents.google.com/patent/US6326364B1/en.
Managlia E, Katzman RB, Brown JB, Barrett TA (2013) Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflamm Bowel Dis 19(10):2051–2060. https://doi.org/10.1097/MIB.0b013e318297d741
Moro-Agud M (2018) Severe febrile neutropenia induced by mesalazine. Med Clin 151(6):e33–e34
Moura RM, Hartmann RM, Licks F, Schemitt EG, Colares JR, doCoutoSoaresFillmannFillmannMarroni MLSHSNP (2016) Antioxidant effect of mesalazine in the experimental colitis model induced by acetic acid. J Coloproctol (rio j) 36(3):139–148. https://doi.org/10.1016/j.jcol.2016.03.003
Olaisen M, Spigset O, Flatberg A, AvB G, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC (2019) Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 49(10):1301–1313. https://doi.org/10.1111/apt.15227
Parenti S, Ferrarini F, Zini R, Montanari M, Losi L, Canovi B, Ferrari S, Grande A (2010) Mesalazine inhibits the β-catenin signalling pathway acting through the upregulation of μ-protocadherin gene in colo-rectal cancer cells. Aliment Pharmacol Ther 31(1):108–119. https://doi.org/10.1111/j.1365-2036.2009.04149.x
Pazoki H, Homayounfar H, Banaei Givi S (2005) The assessment of 5-aminosalicylic acid (5-ASA) effect on ischemia-reperfusion injury of the kidney in rats. RJMS 12(48):63–68. http://rjms.iums.ac.ir/article-1-512-en.html
Pearson DC, Jourd’Heuil D, Meddings JB (1996) The anti-oxidant properties of 5-aminosalicylic acid. Free Radic Biol Med 21(3):367–373. https://doi.org/10.1016/0891-5849(96)00031-7
Pereira SR, Almeida LM, Dinis TC (2019) Improving the anti-inflammatory activity of 5-aminosalicylic acid by combination with cyanidin-3-glucoside: an in vitro study. J Funct Foods 63:103586. https://doi.org/10.1016/j.jff.2019.103586
Qu T, Wang E, Jin B, Li W, Liu R, Zhao Z-b (2017) 5-Aminosalicylic acid inhibits inflammatory responses by suppressing JNK and p38 activity in murine macrophages. Immunopharmacol Immunotoxicol 39(1):45–53. https://doi.org/10.1080/08923973.2016.1274997
Raju KRS, Kumar MS, Gupta S, Naga ST, Shankar JK, Murthy V, Madhunapanthula SRV, Mulukutla S, Ambhore NS, Tummala S (2014) 5-Aminosalicylic acid attenuates allergen-induced airway inflammation and oxidative stress in asthma. Pulm Pharmacol Ther 29(2):209–216. https://doi.org/10.1016/j.pupt.2014.07.007
Ramadan A, Afifi N, Yassin NZ, Abdel-Rahman RF, Abd El-Rahman SS, Fayed HM (2018) Mesalazine, an osteopontin inhibitor: the potential prophylactic and remedial roles in induced liver fibrosis in rats. Chem Biol Interact 289:109–118. https://doi.org/10.1016/j.cbi.2018.05.002
Rezaei N, Eftekhari MH, Tanideh N, Mokhtari M, Bagheri Z (2019) Comparison of antioxidant and anti-inflammatory effects of honey and spirulina platensis with sulfasalazine and mesalazine on acetic acid-induced ulcerative colitis in rats. Galen Med J 8:1095. https://doi.org/10.31661/gmj.v8i0.1095
Riley S, Mani V, Goodman M, Herd M, Dutt S, Turnberg L (1988) Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 29(5):669–674. https://doi.org/10.1136/gut.29.5.669
Roda G, Marocchi M, Sartini A, Roda E (2011) Cytokine networks in ulcerative colitis. Ulcers 2011:391787. https://doi.org/10.1155/2011/391787
Sanapalli BKR, Kannan E, Balasubramanian S, Natarajan J, Baruah UK, Karri VVSR (2018) Pluronic lecithin organogel of 5-aminosalicylic acid for wound healing. Drug Dev Ind Pharm 44(10):1650–1658. https://doi.org/10.1080/03639045.2018.1483393
Sardo HS, Saremnejad F, Bagheri S, Akhgari A, Garekani HA, Sadeghi F (2019) A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. Int J Pharm 558:367–379. https://doi.org/10.1016/j.ijpharm.2019.01.022
Scholar E (2009) Mesalamine. In: Enna SJ, Bylund DB (eds) xPharm: the comprehensive pharmacology reference. Elsevier, New York, pp 1–6. https://doi.org/10.1016/B978-008055232-3.62134-8
Sehgal P, Colombel JF, Aboubakr A, Narula N (2018) Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther 47(12):1597–1609. https://doi.org/10.1111/apt.14688
Sener A, Sahbaz A, Sener LT, Tekkesin MS, Kaya B (2018) Effect of intra-abdominally administered mesalazine (5-aminosalicylic acid) in experimental peritonitis. North Clin Istanb 5(3):171. https://doi.org/10.14744/nci.2017.48379
Simon H, Fischer T, Almási A, Fischer E (2017) Effects of mesalazine on morphological and functional changes in the indomethacin-induced inflammatory bowel disease (rat model of crohn’s disease). Pathol Oncol Res 23(1):41–46. https://doi.org/10.1007/s12253-016-0069-2
Smedegård G, Björk J (1995) Sulphasalazine: mechanism of action in rheumatoid arthritis. Rheumatology 34(2):7–15. https://doi.org/10.1093/rheumatology/XXXIV.suppl_2.7
Soliman MH, Mohamed GG (2013) Cr (III), Mn (II), Fe (III), Co (II), Ni (II), Cu (II) and Zn (II) new complexes of 5-aminosalicylic acid: spectroscopic, thermal characterization and biological activity studies. Spectrochim Acta A 107:8–15. https://doi.org/10.1016/j.saa.2013.01.021
Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G (2008) Cyclooxygenase-2-dependent and-independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75(3):668–676. https://doi.org/10.1016/j.bcp.2007.09.020
Stolfi C, Pallone F, Monteleone G (2012) Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol 2012:980458. https://doi.org/10.1155/2012/980458
Stolfi C, De Simone V, Pallone F, Monteleone G (2013) Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci 14(9):17972–17985. https://doi.org/10.3390/ijms140917972
Tamai H, Kachur JF, Grisham MB, Gaginella TS (1991) Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidants: Possible contribution to the mechanism of action in inflammatory bowel disease. Biochem Pharmacol 41(6–7):1001–1006. https://doi.org/10.1016/0006-2952(91)90207-L
Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K (2019) Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol 30(1):1–10. https://doi.org/10.1515/jbcpp-2018-0036
Tursi A, Brandimarte G, Giorgetti GM, Elisei W (2007) Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 52(3):671–674. https://doi.org/10.1007/s10620-006-9551-0
Williams C, Panaccione R, Ghosh S, Rioux K (2011) Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol 4(4):237–248. https://doi.org/10.1177/1756283X11405250
Yamada T, Volkmer C, Grisham M (1990) Antioxidant properties of 5-ASA: potential mechanism for its anti-inflammatory activity. Can J Gastroenterol 4(7):295–302. https://doi.org/10.1155/1990/324287
Yamada T, Volkmer C, Grisham MB (1991) The effects of sulfasalazine metabolites on hemoglobin-catalyzed lipid peroxidation. Free Radic Biol Med 10(1):41–49. https://doi.org/10.1016/0891-5849(91)90020-4
Yang LP, McCormack PL (2011) MMX® mesalazine. Drugs 71(2):221–235. https://doi.org/10.2165/11205870-000000000-00000
Zhao L-N, Li J-Y, Yu T, Chen G-C, Yuan Y-H, Chen Q-K (2014) 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS ONE 9(4):e94208. https://doi.org/10.1371/journal.pone.0094208
Funding
This research received no any non-external funding and external funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that he has no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Beiranvand, M. A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug. Inflammopharmacol 29, 1279–1290 (2021). https://doi.org/10.1007/s10787-021-00856-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-021-00856-1